Associations - CREBBP mutation

CREBBP mutation CREBBP mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	CREBBP mutation CREBBP mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: C3 – Early Trials	ibrutinib Sensitive: C3 – Early Trials
CREBBP mutation CREBBP mutation	Colorectal Cancer CRC	CREBBP mutation CREBBP mutation	Colorectal Cancer CRC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
CREBBP mutation CREBBP mutation	Colorectal Cancer CRC	CREBBP mutation CREBBP mutation	Colorectal Cancer CRC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
CREBBP mutation CREBBP mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	CREBBP mutation CREBBP mutation	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: C3 – Early Trials	R-CHOP Sensitive: C3 – Early Trials
CREBBP mutation CREBBP mutation	Bladder Cancer Bladder Cancer	CREBBP mutation CREBBP mutation	Bladder Cancer Bladder Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
CREBBP mutation CREBBP mutation	Follicular Lymphoma Follicular Lymphoma	CREBBP mutation CREBBP mutation	Follicular Lymphoma Follicular Lymphoma	YF2 Sensitive: D – Preclinical	YF2 Sensitive: D – Preclinical
CREBBP mutation CREBBP mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	CREBBP mutation CREBBP mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	CDK6 inhibitor Sensitive: D – Preclinical	CDK6 inhibitor Sensitive: D – Preclinical
CREBBP mutation CREBBP mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	CREBBP mutation CREBBP mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	CDK4 inhibitor Sensitive: D – Preclinical	CDK4 inhibitor Sensitive: D – Preclinical